Voyager Therapeutics Inc. (NASDAQ:VYGR) rose 4.7% on Friday . The stock traded as high as $12.90 and last traded at $12.49, with a volume of 132,291 shares. The stock had previously closed at $11.93.

VYGR has been the subject of a number of recent analyst reports. Zacks Investment Research raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 7th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Voyager Therapeutics in a report on Saturday, April 30th. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Voyager Therapeutics in a report on Sunday, March 20th. Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a report on Wednesday, June 22nd. Finally, Wells Fargo & Co. initiated coverage on Voyager Therapeutics in a report on Friday, May 20th. They set an “outperform” rating for the company. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.25.

The firm’s market capitalization is $339.44 million. The company has a 50-day moving average of $12.81 and a 200 day moving average of $12.03.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Thursday, May 12th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.67. On average, equities research analysts forecast that Voyager Therapeutics Inc. will post ($1.46) EPS for the current fiscal year.

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.